Literature DB >> 19038302

Comparison of immunogenicity of five MSP1-based malaria vaccine candidate antigens in rabbits.

Zarifah Hussain Reed1, Marie Paule Kieny, Howard Engers, Martin Friede, Sandra Chang, Shirley Longacre, Pawan Malhotra, Weiqing Pan, Carole Long.   

Abstract

A number of laboratories around the world are producing Plasmodium falciparum erythrocyte-stage vaccine candidates in the pursuit of a vaccine against clinical malaria disease. These candidates are often based on the same parasite protein. Rigorous clinical development and testing of multiple candidates is limited by available resources, which underscores the need to conduct comparative studies of the different vaccine candidates. The purpose of this study was to compare five different candidate proteins all based on P. falciparum merozoite surface protein-1 (MSP1). After investigators submitted their candidates, basic protein profiles were evaluated in a blinded fashion by an independent laboratory, and groups of rabbits were immunized with the proteins. Sera obtained from the rabbits were compared for antibody titers by ELISA and for functional activity by an in vitro parasite growth inhibition assay (GIA) activity, again in a blinded fashion. In selected cases the fine specificity of the antibodies was assessed. Significant differences in immunogenicity as well as the functional activity of antibodies induced by the various vaccine candidates were noted. Data from this study can assist in making decisions for further clinical development of MSP1-based candidates, and this process sets a precedent for future comparisons of malaria vaccine candidates.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19038302     DOI: 10.1016/j.vaccine.2008.10.093

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  17 in total

1.  Plasmodium falciparum 19-kilodalton merozoite surface protein 1 (MSP1)-specific antibodies that interfere with parasite growth in vitro can inhibit MSP1 processing, merozoite invasion, and intracellular parasite development.

Authors:  David K Moss; Edmond J Remarque; Bart W Faber; David R Cavanagh; David E Arnot; Alan W Thomas; Anthony A Holder
Journal:  Infect Immun       Date:  2011-12-27       Impact factor: 3.441

2.  Inhibitory antibodies specific for the 19-kilodalton fragment of merozoite surface protein 1 do not correlate with delayed appearance of infection with Plasmodium falciparum in semi-immune individuals in Vietnam.

Authors:  E Elsa Herdiana Murhandarwati; Lina Wang; Casilda G Black; Doan Hanh Nhan; Thomas L Richie; Ross L Coppel
Journal:  Infect Immun       Date:  2009-07-20       Impact factor: 3.441

3.  Plasmodium berghei circumvents immune responses induced by merozoite surface protein 1- and apical membrane antigen 1-based vaccines.

Authors:  Shigeto Yoshida; Hiroshi Nagumo; Takashi Yokomine; Hitomi Araki; Ayaka Suzuki; Hiroyuki Matsuoka
Journal:  PLoS One       Date:  2010-10-28       Impact factor: 3.240

4.  Genetic linkage of autologous T cell epitopes in a chimeric recombinant construct improves anti-parasite and anti-disease protective effect of a malaria vaccine candidate.

Authors:  Balwan Singh; Monica Cabrera-Mora; Jianlin Jiang; Mary Galinski; Alberto Moreno
Journal:  Vaccine       Date:  2010-01-22       Impact factor: 3.641

5.  Growth-inhibitory antibodies are not necessary for protective immunity to malaria infection.

Authors:  E Elsa Herdiana Murhandarwati; Lina Wang; Harini D de Silva; Charles Ma; Magdalena Plebanski; Casilda G Black; Ross L Coppel
Journal:  Infect Immun       Date:  2009-11-16       Impact factor: 3.441

6.  In vitro growth-inhibitory activity and malaria risk in a cohort study in mali.

Authors:  Peter D Crompton; Kazutoyo Miura; Boubacar Traore; Kassoum Kayentao; Aissata Ongoiba; Greta Weiss; Safiatou Doumbo; Didier Doumtabe; Younoussou Kone; Chiung-Yu Huang; Ogobara K Doumbo; Louis H Miller; Carole A Long; Susan K Pierce
Journal:  Infect Immun       Date:  2009-11-16       Impact factor: 3.441

7.  Tailoring subunit vaccine immunogenicity: maximizing antibody and T cell responses by using combinations of adenovirus, poxvirus and protein-adjuvant vaccines against Plasmodium falciparum MSP1.

Authors:  Alexander D Douglas; Simone C de Cassan; Matthew D J Dicks; Sarah C Gilbert; Adrian V S Hill; Simon J Draper
Journal:  Vaccine       Date:  2010-10-18       Impact factor: 3.641

8.  MSP-1p42-specific antibodies affect growth and development of intra-erythrocytic parasites of Plasmodium falciparum.

Authors:  Elke S Bergmann-Leitner; Elizabeth H Duncan; Evelina Angov
Journal:  Malar J       Date:  2009-08-03       Impact factor: 2.979

9.  New insights for native production of MSP1(19), the disulfide-rich C-terminal fragment from Plasmodium falciparum merozoite surface protein 1.

Authors:  Anne-Gaëlle Planson; J Iñaki Guijarro; Alain F Chaffotte
Journal:  PLoS One       Date:  2013-02-22       Impact factor: 3.240

10.  Impact of pre-existing MSP1(42)-allele specific immunity on potency of an erythrocytic Plasmodium falciparum vaccine.

Authors:  Elke S Bergmann-Leitner; Elizabeth H Duncan; Ryan M Mease; Evelina Angov
Journal:  Malar J       Date:  2012-09-07       Impact factor: 2.979

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.